ISB News

How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells

In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

Cristina Puig Saus, PhD, who led the work, and co-authors Antoni Ribas, PhD, and Jim Heath, PhD, sat down to discuss the work and its future implications. You can watch that video here, or by playing the video at the top of this page.

For more information about the Nature paper, you can read the UCLA Health story here.

 

Recent Articles

  • COVID-19 Vaccines and Boosters Are Essential for Maternal-Fetal Health

    In light of the recent FDA and CDC decision to approve two updated messenger RNA COVID-19 booster shots, it is imperative to alert the pregnant population of the importance and effectiveness of these vaccines and boosters. 

  • 2023 ISB Virtual Microbiome Series

    2023 ISB Virtual Microbiome Series Registration Now Open!

    On October 11-13, 2023, ISB will host a virtual course and symposium on how the ecology of our guts protects us from pathogens. Both events are virtual and free. The intended audience for these events are graduate students, postdocs, principal investigators, industry scientists, educators, clinicians, or any other variety of microbiome-curious person from across the globe.

  • Baliga Postdoctoral Fellow Training

    Genetic Tools Probe Microbial Dark Matter

    ISB researchers Nitin Baliga, Serdar Turkarslan, Mario Arrieta-Ortiz and Yaqiao Li collaborated with the University of Washington to present the first glimpse of the molecular mechanisms behind the unusual lifestyle of a group of tiny microbes called Patescibacteria. The breakthrough was made possible by the discovery of a way to genetically manipulate these bacteria, an advance that has opened a world of possible new research directions.